Skip to main content
OpenTrials
Completed

NCT Number: NCT06122961

Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

This study will collect medical and background information from participants with diseases that affect the heart and blood vessels (cardiovascular disease). Participants will continue their normal care and will not get any treatment other than those the study doctor has prescribed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiovascular Risk Cardiovascular Diseases Chronic Disease Chronic Kidney Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Heart Diseases Heart Failure Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Italiano Regional Sur, Bahía Blanca, Buenos Aires, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study.
  • Age 18 years or above at the time of signing the informed consent.
  • Presence of ASCVD (atherosclerotic cardiovascular disease) and/or HF (heart failure)
  • Presence of serum creatinine in the medical chart within 24 months prior to signing of informed consent (for ASCVD patients only).

Exclusion criteria

  • Previous participation in this study. Participation is defined as having given informed consent in this study.
  • Current participation (i.e., signed informed consent) in any other interventional clinical study.
  • Any hospitalization or unplanned visit within the last 60 days (including exacerbation of chronic disease with hospitalization).
  • Clinical evidence, or suspicion of, active infection within the last 60 days.
  • Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation

Treatment and study plan

No treatment given

Other

No treatment given

Primary outcomes

  1. High sensitivity C-reactive protein (hsCRP) greater than or equal to 2 mg/L (yes/ no)

    Time frame: At visit (day 0)

    Count of patient

Secondary outcomes

  1. Interleukin 6 (IL-6)

    Time frame: At visit (day 0)

    pg/ml

  2. N-terminal prohormone of brain natriuretic peptide (NT-proBNP)

    Time frame: At visit (day 0)

    pg/ml

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

Prevalence of Systemic Inflammation in Patients With Atherosclerotic Cardiovascular Disease and Heart Failure

Acronym: POSEIDON

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Nov 8, 2023
Registry last updated
May 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.